Megan Ingram
Subscribe to Megan Ingram's PostsMegan Ingram focuses her practice on assessing and mitigating antitrust risk in public and private M&A transactions. She supports US and international clients with merger review, obtaining clearance under the Hart-Scott-Rodino Act, antitrust compliance, and governmental antitrust investigations. Megan has experience across multiple industries, including software and technology, healthcare and life sciences, consumer products, aerospace and defense, and industrials. Read Megan Ingram's full bio.
Antitrust Under Trump: June 2025 Updates
By Jon B. Dubrow, Michelle Lowery and Megan Ingram on Jun 16, 2025
Posted In DOJ Developments, FTC Developments, Mergers & Acquisitions
The Trump administration‘s antitrust landscape continues to evolve, with a return to structural remedies, increased transparency in merger settlements, and skepticism toward innovation defenses in tech deals. The US Department of Justice (DOJ) and Federal Trade Commission (FTC) are also actively promoting faster merger reviews and emphasizing strong divestiture standards. Read more here.
Continue Reading
Antitrust Under Trump: April 2025 Updates
By Jon B. Dubrow, Michelle Lowery and Megan Ingram on Apr 29, 2025
Posted In Consumer Protection/Privacy, DOJ Developments, FTC Developments, Mergers & Acquisitions
The Trump administration’s antitrust landscape continues to develop with key changes in industry and policy priorities, remedy expectations, and agency personnel. Among the updates, Mark Meador was confirmed as a commissioner of the Federal Trade Commission, President Trump signed an executive order to eliminate anticompetitive regulations, and the Department of Justice is partial to populist...
Continue Reading
Heard at the 2025 Antitrust Law Section Spring Meeting
By Lisa P. Rumin, Reese Poncia, Anthony S. Ferrara, Elai Katz, Megan Ingram, Royce Brosseau, Claire Danberg, Betty Zhang and Alex Grayson on Apr 10, 2025
Posted In Cartel Enforcement, Consumer Protection/Privacy, DOJ Developments, EC Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
The American Bar Association Antitrust Law Section held its annual Spring Meeting from April 2 to 5 in Washington, DC, where federal, state, and international antitrust enforcers shared key updates and enforcement priorities. At the Spring Meeting, antitrust agencies signaled continued scrutiny of mergers, noncompete agreements, and Big Tech – plus an uptick in state-level...
Continue Reading
Antitrust Under Trump: March 2025 Updates
By Jon B. Dubrow, Michelle Lowery and Megan Ingram on Apr 1, 2025
Posted In DOJ Developments, FTC Developments
The Trump administration has taken significant steps to reshape antitrust enforcement by exerting greater control over the Federal Trade Commission (FTC), firing two Democratic FTC commissioners. Leadership has also begun to outline more of their priorities in speeches and interviews. These changes outline antitrust enforcement priorities, with a stronger emphasis on economic analysis and litigation...
Continue Reading
Antitrust Under Trump: Initial Policies and Actions
By Jon B. Dubrow, Michelle Lowery and Megan Ingram on Mar 6, 2025
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Joint Ventures/Competitor Collaboration, Mergers & Acquisitions, Monopolization/Abuse of Dominance
The Trump administration has initiated significant changes in antitrust policy through key appointments and policy announcements. The administration announced that the Federal Trade Commission (FTC) and US Department of Justice (DOJ) will continue using the 2023 Merger Guidelines and expressed support for new Hart-Scott-Rodino (HSR) rules. Additionally, the FTC outlined its goals, which include improving...
Continue Reading
